Friday , November 15 2019
Home / senegal / Skyhawk Therapeutics announces an agreement with Genentech for the discovery and development of small molecular modifiers of RNA splicing of oncological and neurodegenerative molecules

Skyhawk Therapeutics announces an agreement with Genentech for the discovery and development of small molecular modifiers of RNA splicing of oncological and neurodegenerative molecules



[ad_1]

Skyhawk will use its SkySTARTM platform to develop candidates for medications aimed at multiple oncology and neurodegenerative diseases. In return, Skyhawk will receive a payment in advance and could earn more than $ 2,000,000 over time, including selective shares and payouts, as well as rights over the sale of commercialized medicines.

WALTHAM, Massachusetts, July 16, 2019 / PRNewswire / – Skyhawk Therapeutics, Inc. (Skyhawk) announced today that it has signed an exclusive and multiple-choice license agreement with Genentech, member of the Roche Group, to develop and market small molecules that modify RNA splicing. Skyhawk will use its SkySTAR technology platformTM Discover and develop innovative treatments of small molecules aimed at specific oncology and neurological goals. This agreement gives Genentech an exclusive worldwide license to develop and market potential multi-purpose therapeutic solutions, while Skyhawk will be prepaid and will receive payments and royalties in the future. As part of this agreement, Genentech will be responsible for clinical development and commercialization.

"Genentech has been one of the leaders in the promotion of the discovery of drugs for oncology and neurodegenerative disorders," explains Bill Haney, co-founder and CEO of Skyhawk. "We hope to continue to show the utility of SkySTAR ™ to discover new RNA splitters that target important goals in the treatment of neurodegenerative diseases and cancer. We share Genentech's passion for the transformation of patients' lives, and we hope to work with the Genentech team to finally expand the therapeutic options available to patients. "

"RNA splicing modulation represents an unprecedented approach to diseases that are difficult to treat," he adds James Sabry, M.D., Ph.D., global manager of pharmaceutical associations in Roche. "Skyhawk has acquired a unique experience in biology of the joint, and we are very happy to work with your team to discover new potential medications for patients with cancer and neurodegeneration."

About Skyhawk Therapeutics
Skyhawk Therapeutics focuses on discovering, developing and marketing treatments through its new SkySTAR ™ platform (") Skyhawk Small Alternative therapy for alternative splicing of "RNA" or therapeutic of small molecules for alternative splicing of the Skyhawk RNA), to develop small molecule medications that offer innovative therapies to patients.

[ad_2]
Source link